Overview

Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This study is being performed to evaluate the safety and tolerability of the TRC093 antibody.
Phase:
Phase 1
Details
Lead Sponsor:
Tracon Pharmaceuticals Inc.
Treatments:
Antibodies
Antibodies, Monoclonal
Immunoglobulins